CAMBRIDGE, Mass.--(BUSINESS WIRE)--
- Continued progress towards 2022 vision of four marketed gene and cell therapy products with robust development pipeline -
- ZYNTEGLO commercial launch advancing with European Medicines Agency approval of refined commercial manufacturing process -
- Ended quarter with $1.41 billion in cash, cash equivalents and marketable securities
bluebird bio, Inc. (BLUE) today reported financial results and business highlights for the third quarter ended September 30, 2019.
During the third quarter we advanced our country-by-country launch plans in Europe and, with the recent approval of the commercial drug product manufacturing specifications for ZYNTEGLO, we moved one step closer to our goal of treating patients suffering from TDT in early 2020, said Nick Leschly, chief bluebird. Also this quarter, we presented updated data from the Phase 2/3 Starbeam study in patients with CALD. To report that patients continued to be free of MFDs at up to five years of follow-up is something were tremendously proud to do for these families, and we look forward to advancing that program in the regulatory process next year. Looking ahead, we plan to provide clinical updates for ZYNTEGLO and across the rest of our portfolio, including LentiGlobin in sickle cell disease, bb21217 in multiple myeloma, and from our registration-enabling KarMMa study of ide-cel in patients with multiple myeloma by the end of this year. Id like to thank all the bluebirds around the globe for their tireless focus on doing the right thing for our patients weve seen amazing progress thus far in 2019 and I look forward to ending the year on a strong note.
Recent Highlights:
TDT
ZYNTEGLO COMMERCIAL READINESS In October, bluebird bio announced that the European Medicines Agency (EMA) approved the refined commercial drug product manufacturing specifications for ZYNTEGLO (autologous CD34+ cells encoding A-T87Q-globin gene), a one-time gene therapy for patients 12 years and older with transfusion-dependent -thalassemia (TDT) who do not have a 0/0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. With this update, apceth is in the final stages of preparing to manufacture ZYNTEGLO for commercial use. The company continues to proceed with discussions on value-based payment agreements and Qualified Treatment Center contracts and expects to treat the first commercial patient in early 2020.
CALD
Story continues
DATA FROM STARBEAM STUDY (ALD-102) AND ALD-103 PRESENTED At the 13th European Pediatric Neurology Society (EPNS) Congress in September 2019, bluebird bio presented new data from the clinical development program for its investigational studies of Lenti-D gene therapy in patients with cerebral adrenoleukodystrophy: updated data from the Phase 2/3 Starbeam study (ALD-102) in boys 17 years of age and under with CALD and updated data from the ongoing observational study (ALD-103) of allogeneic hematopoietic stem cell transplant (allo-HSCT) in boys 17 years of age and under with CALD. Long-term follow-up data as of April 2019 showed that the 88% of patients treated in the Starbeam study (ALD-102) were free of major functional disabilities (MFDs) at two years, and continued to remain MFD-free at up to five years of follow-up.
COMPANY
FIRST PATIENT TREATED IN PHASE 1/2 TRIAL FOR MERKEL CELL CARCINOMA (MCC) In August 2019, Fred Hutchinson Cancer Research Center infused the first patient in their proof-of-concept phase 1/2 single-arm study evaluating Merkel Cell Polyomavirus (MCPyV) TCR-engineered autologous T cells in combination with avelumab (anti-PDL1) for the treatment of MCC. Results from the academic phase 1/2 single-arm study are expected to inform next-generation T cell approaches including TCR engineering and checkpoint inhibition. The study will enroll approximately 16 patients. Development of this program is led by Fred Hutchinson Cancer Research Center. bluebird bio retains the exclusive option to license this program.
NOVO NORDISK COLLABORATION In October 2019, bluebird bio and Novo Nordisk announced a research collaboration to jointly develop next-generation in vivo genome editing treatments for genetic diseases, including hemophilia. During the three-year research collaboration, bluebird and Novo Nordisk will focus on identifying a development gene therapy candidate with the ambition of offering people with hemophilia A a lifetime free of factor replacement therapy.
MANAGEMENT UPDATE In October 2019, bluebird bio announced that Jeffrey T. Walsh, chief strategy officer, has decided to transition from his current role effective January 6, 2020. Jeff has not only built a strong foundation for bluebirds overall growth strategy but also leaves an experienced and passionate team. Both Chip Baird, chief financial officer, and Joanne Smith-Farrell, chief business officer, will assume broader corporate development and strategic responsibilities as bluebird continues to deliver on its mission for patients.
NEW BOARD APPOINTMENT In September 2019, bluebird bio announced the appointment of William R. Sellers, M.D. to its Board of Directors.
Upcoming Anticipated Milestones:
TDT
Initiation of a rolling Biologics Licensing Application submission to the U.S. FDA for ZYNTEGLO in patients with TDT and non-0/0 genotypes by the end of 2019
Presentation of ZYNTEGLO clinical data from the Northstar-2 (HGB-207) clinical study in patients with TDT and non-0/0 genotypes by the end of 2019
Presentation of ZYNTEGLO clinical data from the Northstar-3 (HGB-212) clinical study in patients with TDT and a 0/0 genotype or an IVS-I-110 mutation by the end of 2019
SCD
Phase 3 HGB-210 study of LentiGlobin in patients with SCD open and enrolling by the end of 2019
Presentation of LentiGlobin clinical data from the HGB-206 clinical study in patients with SCD by the end of 2019
Multiple Myeloma
Ide-cel clinical data update from the registration-enabling KarMMa study in patients with relapsed/refractory multiple myeloma by the end of 2019
Presentation of bb21217 clinical data from the CRB-402 clinical study in patients with relapsed/refractory multiple myeloma by the end of 2019
Third Quarter 2019 Financial Results
Cash Position: Cash, cash equivalents and marketable securities as of September 30, 2019 and December 31, 2018 were $1.41 billion and $1.89 billion, respectively. The decrease in cash, cash equivalents and marketable securities is primarily related to cash used in support of ordinary course operating activities and cash used to purchase property, plant and equipment, including those purchases related to the companys buildout of its manufacturing facility in Durham, North Carolina.
Revenues: Collaboration and license and royalty revenues were $8.9 million for the three months ended September 30, 2019 compared to $11.5 million for the three months ended September 30, 2018. Collaboration and license and royalty revenues were $34.7 million for the nine months ended September 30, 2019 compared to $35.3 million for the nine months ended September 30, 2018. The decrease in both periods was primarily attributable to a decrease in collaboration revenue under our arrangement with Celgene, partially offset by an increase in license and royalty revenue and collaboration revenue under our arrangement with Regeneron.
R&D Expenses: Research and development expenses were $151.4 million for the three months ended September 30, 2019 compared to $116.7 million for the three months ended September 30, 2018. Research and development expenses were $420.6 million for the nine months ended September 30, 2019 compared to $328.9 million for the nine months ended September 30, 2018. The increase in both periods was primarily driven by costs incurred to advance and expand the companys pipeline.
G&A Expenses: General and administrative expenses were $66.3 million for the three months ended September 30, 2019 compared to $44.5 million for the three months ended September 30, 2018. General and administrative expenses were $195.2 million for the nine months ended September 30, 2019 compared to $120.6 million for the nine months ended September 30, 2018. The increase in both periods was largely attributable to costs incurred to support the companys ongoing operations and growth of its pipeline as well as commercial-readiness activities.
Net Loss: Net loss was $206.0 million for the three months ended September 30, 2019 compared to $145.5 million for the three months ended September 30, 2018. Net loss was $566.3 million for the nine months ended September 30, 2019 compared to $406.6 million for the nine months ended September 30, 2018.
About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, were developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, were working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.
bluebird bio is a human company powered by human stories. Were putting our care and expertise to work across a spectrum of disorders by researching cerebral adrenoleukodystrophy, sickle cell disease, transfusion-dependent -thalassemia and multiple myeloma using three gene therapy technologies: gene addition, cell therapy and (megaTAL-enabled) gene editing.
bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and Zug, Switzerland. For more information, visit bluebirdbio.com.
Follow bluebird bio on social media: @bluebirdbio, LinkedIn, Instagram and YouTube.
ZYNTEGLO, LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
The full common name for ZYNTEGLO: A genetically modified autologous CD34+ cell enriched population that contains hematopoietic stem cells transduced with lentiviral vector encoding the A-T87Q-globin gene.
Forward-Looking Statements This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the companys financial condition, results of operations, as well as statements regarding the plans for regulatory submissions and commercialization for ZYNTEGLO and the companys product candidates, including anticipated regulatory milestones, planned commercial launches, planned clinical studies, as well as the companys intentions regarding the timing for providing further updates on the development and commercialization of ZYNTEGLO and the companys product candidates. Any forward-looking statements are based on managements current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the preliminary positive efficacy and safety results from our prior and ongoing clinical trials will not continue or be repeated in our ongoing or future clinical trials, the risk of cessation or delay of any of the ongoing or planned clinical studies and/or our development of our product candidates, risks that the current or planned clinical trials of our product candidates will be insufficient to support regulatory submissions or marketing approval in the United States and European Union, the risk that we will encounter challenges in the commercial launch of ZYNTEGLO in the European Union, including in managing our complex supply chain for the delivery of drug product or in the adoption of value-based payment models or in obtaining sufficient coverage or reimbursement for our products if approved, the risk that our collaborations, including the collaboration with Celgene, will not continue or will not be successful, and the risk that any one or more of our product candidates, will not be successfully developed, approved or commercialized. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled Risk Factors in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and bluebird bio undertakes no duty to update this information unless required by law.
bluebird bio, Inc. Consolidated Statements of Operations (in thousands, except per share data) (unaudited)
For the three months ended September 30,
For the nine months ended September 30,
2019
2018
2019
2018
Revenue:
Collaboration revenue
$
6,575
$
10,926
$
29,310
$
33,971
License and royalty revenue
2,335
602
Excerpt from:
bluebird bio Reports Third Quarter 2019 Financial Results and Highlights Operational Progress - Yahoo Finance
- Wu stem cell medical center hospital introduction video.avi [Last Updated On: August 4th, 2011] [Originally Added On: August 4th, 2011]
- Cerebral palsy patient Bianca after stem cell treatment 1.wmv [Last Updated On: August 4th, 2011] [Originally Added On: August 4th, 2011]
- Cerebral palsy patient Atillia before stem cell treatment 2.wmv [Last Updated On: August 4th, 2011] [Originally Added On: August 4th, 2011]
- SCI_Celine_French_ifting_her_arms.wmv [Last Updated On: August 5th, 2011] [Originally Added On: August 5th, 2011]
- Cerebral palsy patient Atillia after stem cell treatment 1.wmv [Last Updated On: August 5th, 2011] [Originally Added On: August 5th, 2011]
- MSA_Dezmond_USA_before2.wmv [Last Updated On: August 6th, 2011] [Originally Added On: August 6th, 2011]
- MSA_Dezmond_USA_after1.wmv [Last Updated On: August 7th, 2011] [Originally Added On: August 7th, 2011]
- Parkinson_Jane_Scotland_before1.wmv [Last Updated On: August 7th, 2011] [Originally Added On: August 7th, 2011]
- Cerebral palsy patient Atillia after stem cell treatment 2.wmv [Last Updated On: August 7th, 2011] [Originally Added On: August 7th, 2011]
- Stroke_Li_China_after1.wmv [Last Updated On: August 8th, 2011] [Originally Added On: August 8th, 2011]
- SCI_Cartaze_USA_after1.wmv [Last Updated On: August 9th, 2011] [Originally Added On: August 9th, 2011]
- SCI_Cartaze_USA_after3.wmv [Last Updated On: August 9th, 2011] [Originally Added On: August 9th, 2011]
- Cerebral palsy patient Bianca before stem cell treatment 3.wmv [Last Updated On: August 10th, 2011] [Originally Added On: August 10th, 2011]
- Parkinson_Michael_USA_before1.wmv [Last Updated On: August 13th, 2011] [Originally Added On: August 13th, 2011]
- Cerebral palsy patient Gabor after stem cell treatment 3.1.wmv [Last Updated On: August 14th, 2011] [Originally Added On: August 14th, 2011]
- Parkinson_Michael_USA_before3.wmv [Last Updated On: August 17th, 2011] [Originally Added On: August 17th, 2011]
- Cerebral palsy patient Bianca before stem cell treatment 2.wmv [Last Updated On: August 18th, 2011] [Originally Added On: August 18th, 2011]
- Muscular dystrophy patient_Kleber_Brazil.wmv [Last Updated On: August 19th, 2011] [Originally Added On: August 19th, 2011]
- Cerebral palsy patient Bianca before stem cell treatment 1.wmv [Last Updated On: August 19th, 2011] [Originally Added On: August 19th, 2011]
- Parkinson_David_USA_before1.wmv [Last Updated On: August 19th, 2011] [Originally Added On: August 19th, 2011]
- SCI_Obaidullah_Pakistan.wmv [Last Updated On: August 23rd, 2011] [Originally Added On: August 23rd, 2011]
- Cerebral palsy patient Bianca after stem cell treatment 3.wmv [Last Updated On: August 25th, 2011] [Originally Added On: August 25th, 2011]
- Parkinson_Jane_Scotland_after2.wmv [Last Updated On: August 26th, 2011] [Originally Added On: August 26th, 2011]
- Parkinson_Michael_USA_before2.wmv [Last Updated On: August 27th, 2011] [Originally Added On: August 27th, 2011]
- Multiple sclerosis_Evangelos_Australia_before1.wmv [Last Updated On: September 1st, 2011] [Originally Added On: September 1st, 2011]
- The Board of Governors Heart Stem Cell Center - Cedars-Sinai Medical Center [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- OSU Medical Center Using Stem Cell Therapy for Critical Limb Ischemia Patients [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Cancer Stem Cells: The Origin of Cancer [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- Human Embryonic stem cell research [Last Updated On: September 8th, 2011] [Originally Added On: September 8th, 2011]
- HIV/AIDS: Spotlight on Stem Cell Research - Loren Leeds [Last Updated On: September 8th, 2011] [Originally Added On: September 8th, 2011]
- Battling and Beating Cancer -- Stem Cell Transplantation Part 1 [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- My first day of apheresis at Duke Medical Center [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- Disease in a Dish: Using Stem Cells to Model Huntington's Disease and Spinal Muscular Atrophy [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- 2010 Stem Cell Transplant Reunion at University of Chicago [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- Reverse Aging - Anti-Aging - Stem Cell Treatment [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- Stem Cell Research Halted At Medical College [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Stem cell centre in Sri Ramachandra Medical Centre [Last Updated On: September 14th, 2011] [Originally Added On: September 14th, 2011]
- Inside a Heart Stem Cell Clinical Trial - Cedars-Sinai Medical Center [Last Updated On: September 14th, 2011] [Originally Added On: September 14th, 2011]
- Stem Cells and Cardiac Regeneration [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- HIV/AIDS: Spotlight on Stem Cell Research - John Zaia [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Stem Cells, The Making Of... [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Parkinson's Disease: Spotlight on Stem Cell Research - Jeff Bronstein [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Life in the Balance: Perspectives on Stem Cell Research [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Jeanette Montufar - Parkinson's at Integra Medical Center [Last Updated On: September 27th, 2011] [Originally Added On: September 27th, 2011]
- Stem Cell Cures or 21st Century Snake Oil? Part 1 [Last Updated On: September 27th, 2011] [Originally Added On: September 27th, 2011]
- Heart cells grown from human embryonic stem cells [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- Arthritis: Spotlight on Stem Cell Research - Mark Genovese [Last Updated On: October 3rd, 2011] [Originally Added On: October 3rd, 2011]
- Parkinson's Disease Stem Cell Treatment [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Hadassah Medical Center Stem Cell Human Embryonic Stem Cells [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Anti-Aging - Stem Cell Treatment for the Family [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Dr Farjo BBC News 24 interview about new stem cell research and hair transplant surgery [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Stem Cell Cure or 21st Century Snake Oil? Part 3 [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Stem cell miracle by FOX TV on Mar 26 2009 [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Arthritis: Spotlight on Stem Cell Research - Bill Robinson [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Asthma Treated at Integra Medical Center with Stem cells [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Dr. Lucy Godley on Stem Cell Transplants [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- Cerebral palsy patient Gabor after stem cell treatment 1.wmv [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- SCI_Saber_Egypt.wmv [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Stroke_Mohd_Saudi_Arabia.wmv [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- SCI_Hammod_Saudi_Arabia.wmv [Last Updated On: October 7th, 2011] [Originally Added On: October 7th, 2011]
- Parkinson_Penny_USA_brfore.wmv [Last Updated On: October 7th, 2011] [Originally Added On: October 7th, 2011]
- Marco Costa MD discusses how stem cells can repair a damaged heart [Last Updated On: October 7th, 2011] [Originally Added On: October 7th, 2011]
- Stem Cell Treatment in Mexico - PlacidWay [Last Updated On: October 8th, 2011] [Originally Added On: October 8th, 2011]
- Parkinson's Disease Stem Cell Treatment - Part 1 [Last Updated On: October 8th, 2011] [Originally Added On: October 8th, 2011]
- Parkinson's Disease Stem Cell Treatment - Part 2 [Last Updated On: October 8th, 2011] [Originally Added On: October 8th, 2011]
- Multiple Sclerosis_Evangelos_Australia_after1.wmv - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Stem Cell Cures or 21st Century Snake Oil? Part 2 - Video [Last Updated On: October 15th, 2011] [Originally Added On: October 15th, 2011]
- SCI_Christian_Alberto_Alvarado_Arce_Guatemala.wmv - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Dr. Lucy Godley on Stem Cell Donations for Transplant - Video [Last Updated On: October 26th, 2011] [Originally Added On: October 26th, 2011]
- Transforming stem cells into functioning organ tissue - Video [Last Updated On: October 26th, 2011] [Originally Added On: October 26th, 2011]
- Medical Treatment by Stem Cells Myth or Reality? Episode 1 - Video [Last Updated On: October 27th, 2011] [Originally Added On: October 27th, 2011]
- New advances in the treatment of cancer through stem cell collection and storage for families. - Video [Last Updated On: October 29th, 2011] [Originally Added On: October 29th, 2011]
- Alzheimer's Stem Cell Research Patient Advocate Spotlight: The Faces of Neurodegenerative Disease - Video [Last Updated On: October 29th, 2011] [Originally Added On: October 29th, 2011]
- Harvesting stem cells from horse bone marrow at UT - Video [Last Updated On: October 31st, 2011] [Originally Added On: October 31st, 2011]
- Allison Sass Follow up after Stem Cell therapy - Video [Last Updated On: November 15th, 2011] [Originally Added On: November 15th, 2011]
- SCI_Celine_French_using_computer.wmv - Video [Last Updated On: November 15th, 2011] [Originally Added On: November 15th, 2011]
- Cardiovascular Therapies: Spotlight on Stem Cell Research - Yung-Wei Chi - Video [Last Updated On: November 16th, 2011] [Originally Added On: November 16th, 2011]
- Noel Ordonez ALS treated at IMC stem cell therapy - Video [Last Updated On: December 5th, 2011] [Originally Added On: December 5th, 2011]
- Brain Tumors: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video [Last Updated On: December 5th, 2011] [Originally Added On: December 5th, 2011]
- Stem Cell Transplantation | Insights [Last Updated On: December 9th, 2011] [Originally Added On: December 9th, 2011]